Clinical Trials Directory

Trials / Unknown

UnknownNCT05054556

Galectin and Respiratory Weaning

Prognostic Value of Galectin-3 for Success of Respiratory Weaning

Status
Unknown
Phase
Study type
Observational
Enrollment
150 (estimated)
Sponsor
Asklepios Neurological Clinic Bad Salzhausen · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Galectin-3 is a biomarker for fibrotic activity. In the course of invasive ventilation, fibrotic changes in the lungs may occur. The study aims to investigate whether the level of galectin-3 levels correlates with clinical weaning parameters.

Detailed description

Galectin-3 (Gal-3) is a protein with an important role in cell-cell adhesion, cell-matrix interactions, macrophage activation, angiogenesis, metastasis and apoptosis. Galectin-3 is expressed in the nucleus, cytoplasm, mitochondrion, cell surface, and extracellular space.It is involved in different biological processes: cell adhesion, cell activation and chemoattraction, cell growth and differentiation, cell cycle, and apoptosis. Several studies revealed the function of galectin-3 in cancer, inflammation and (lung) fibrosis, heart disease, and stroke. Expression of galectin-3 is associated with heart failure, including myofibroblast proliferation, fibrogenesis, tissue repair, inflammation, and ventricular remodeling. A correlation between galectin-3 expression levels and various types of fibrosis has been found. Galectin-3 is upregulated in idiopathic pulmonary fibrosis. Mechanical ventilation can cause lung damage, or worsen it if already present. This phenomenon is called ventilation-induced lung damage. Main mechanisms are high tidal volumes causing overexpansion of the lungs (volutrauma), high airway pressure (barotrauma) and cyclical collapse and reopening of atelectatic alveolar regions (atelectrauma) leading to a pulmonary inflammatory reaction called "bio-trauma". To evaluate the (potential) lung injury serum levels of galectin-3 are measured on admission to our hospital. During respiratory weaning invasiveness of ventilation will be reduced. Data relating biomarkers especially galectin3 during/after successful respiratory weaning are missing. This is why follow up measurements of galectin-3 will be done and correlated with ventilation parameters/duration/ success of respiratory weaning. Prior studies evaluated the role of proGRP and CA 15-3 in patients with lung fibrosis. As a part of the study galectin-3 serum levels will be correlated with serum levels of proGRP and CA 15-3. In summary the aim of this study is to evaluate the diagnostic value of galectin-3 in respiratory weaning.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTLabaratory testsEstimation of serum levels of the following parameters: galectin-3, proBNP, TNI, proGRP, CA15-3, CK, creatinine, urea, crp, pct, leucozytes

Timeline

Start date
2021-11-01
Primary completion
2024-12-31
Completion
2025-06-30
First posted
2021-09-23
Last updated
2023-09-26

Locations

2 sites across 1 country: Germany

Source: ClinicalTrials.gov record NCT05054556. Inclusion in this directory is not an endorsement.